An immunogenic personal neoantigen vaccine for patients with melanoma.

Specific PHGKB|Cancer|PHGKB

Melanoma Genomics

- Cancer PHGKB -

What's New

Last Posted: Dec 21, 2017

---

• An immunogenic personal neoantigen vaccine for patients with melanoma.  
  Ott Patrick A et al. Nature 2017 547(7662) 217-221
• Marshalling the translational potential of MC1R for precision risk assessment of melanoma.  
  Kanetsky Peter A et al. Cancer prevention research (Philadelphia, Pa.) 2017 Dec
• Are Comprehensive Next-generation Sequencing Analyses Really Required for the Management of Patients With Melanoma to Date?  
  Uguen Arnaud et al. Applied immunohistochemistry & molecular morphology : AIMM 2017 Oct
• Development and Evaluation of a Telephone Communication Protocol for the Delivery of Personalized Melanoma Genomic Risk to the General Population.  
  Fenton Georgina L et al. Journal of genetic counseling 2017 Dec
• Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?  
  Branca Mattia et al. Melanoma research 2017 Nov
• Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma.  
  Yao Keluo et al. Applied immunohistochemistry & molecular morphology : AIMM 2017 Nov
• First-In-Human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?  
  Baylis Francoise et al. Current gene therapy 2017 Nov
• Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.  
  Cheng Liang et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2017 Nov
• Genetic prognostication in uveal melanoma.  
  Dogrusöz Mehmet et al. Acta ophthalmologica 2017 Nov
• Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.  
  Morgese Francesca et al. Oncotarget 2017 Sep 8(44) 75914-75923